Home › Peptides

What Is a GLP-1? Ozempic, Wegovy and Mounjaro Explained

By the Strength from the Well Editorial Team · Evidence last reviewed September 2026 · Not reviewed by a licensed clinician (why we say that)

The short answer

GLP-1 stands for glucagon-like peptide-1, a hormone your intestines release after you eat that helps control blood sugar and tells your brain you have had enough. GLP-1 medications are engineered copies of that hormone that last for days instead of minutes, which is why they are given as a weekly or daily injection rather than a pill. Ozempic and Wegovy are the same drug, semaglutide, approved and dosed for different purposes; Mounjaro and Zepbound are both tirzepatide, which acts on a second gut hormone receptor as well.

Key points

GLP-1 is a natural hormone. These drugs are modified versions of it that resist being broken down.
They work in several places at once: pancreas, stomach, and appetite centers in the brain.
Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide.
Which brand name you are prescribed usually reflects which condition it is approved to treat, which matters enormously for insurance.
In trials, average weight loss has been in the range of roughly 15 percent of body weight for semaglutide and around 20 percent for the highest tirzepatide dose, with wide individual variation.
Effects generally fade after stopping, because the underlying biology has not changed.

The hormone before the drug

Your small intestine contains cells that notice when food arrives. When it does, they release glucagon-like peptide-1 into the bloodstream. It is called that because it resembles glucagon, a different hormone, not because it does the same thing.

GLP-1 does several jobs at once. It tells the pancreas to release insulin, but only when blood sugar is elevated, which is why it does not usually cause dangerous low blood sugar on its own. It suppresses glucagon, which otherwise tells the liver to release stored sugar. It slows how quickly the stomach empties, so food and sugar arrive more gradually. And it acts on regions of the brain involved in appetite and reward, producing the feeling of having had enough.

In a healthy body, this happens after every meal and then stops. Natural GLP-1 is destroyed within about two minutes by an enzyme called DPP-4. That short life is the entire reason natural GLP-1 could never be used as a medicine.

How the drugs are engineered

Making GLP-1 into a usable drug meant making it last. Chemists changed the amino acid at the spot where DPP-4 attacks so the enzyme can no longer cut it, and attached a fatty acid chain that lets the molecule cling to albumin, a carrier protein in the blood. The albumin acts as a slow-release reservoir.

The result is a molecule that behaves like the natural hormone at the receptor but lasts about a week instead of two minutes. That is why these are weekly injections. Earlier drugs in the class, like liraglutide, were engineered less aggressively and are taken daily.

Tirzepatide is a further step. It activates the GLP-1 receptor and also the receptor for GIP, a second gut hormone released after eating. Exactly why hitting both produces larger effects is still being worked out, but in head-to-head studies against semaglutide it has produced greater average weight loss.

There is also an oral form of semaglutide, taken daily with strict instructions because only a small fraction of a swallowed dose survives digestion and gets absorbed.

Sorting out the brand names

This confuses almost everyone, and the confusion has real financial consequences.

Semaglutide is the active ingredient in Ozempic, which is approved for type 2 diabetes, and in Wegovy, which is approved for chronic weight management. It is the same molecule, supplied at different maximum doses under different labels. There is also Rybelsus, the oral semaglutide tablet for type 2 diabetes.

Tirzepatide is the active ingredient in Mounjaro, approved for type 2 diabetes, and Zepbound, approved for chronic weight management, with an additional approved use for moderate-to-severe obstructive sleep apnea in adults with obesity.

Other drugs in the family include liraglutide, sold as Victoza for diabetes and Saxenda for weight management, plus dulaglutide and exenatide products.

Why does the naming matter? Because insurance coverage usually follows the approved indication on the label rather than the molecule. A plan may readily cover a GLP-1 prescribed for diabetes and flatly exclude the identical molecule prescribed for weight. That is not a medical judgment. It is a benefit design decision, and it is the single most common reason people are told no.

What the drugs actually do for people

For type 2 diabetes, GLP-1 medications lower blood sugar reliably and, unlike some older options, tend to cause weight loss rather than weight gain. Several drugs in the class have also been shown in large cardiovascular outcome trials to reduce the risk of major cardiovascular events in people with type 2 diabetes and established heart disease, which is why some have added cardiovascular indications to their labels.

For weight, the results were a genuine change in what medication could do. In the main semaglutide weight-management trials, adults without diabetes lost on the order of 15 percent of their starting body weight on average over roughly 68 weeks, alongside lifestyle counseling. In the main tirzepatide trial, average loss at the highest dose was in the neighborhood of 20 percent over about 72 weeks. Averages hide a lot: some people lost far more, and some lost very little. People with type 2 diabetes generally lose less than people without it.

Beyond weight, a large randomized trial in people with overweight or obesity and established cardiovascular disease but not diabetes found that semaglutide reduced the rate of major cardiovascular events compared with placebo. That finding shifted the conversation, because it suggested the benefit is not only about the number on the scale.

What happens when you stop

This is the part that deserves more attention than it gets. In studies where people stopped taking these medications, most regained a substantial portion of the weight they lost, and blood sugar and cardiovascular markers drifted back toward where they started.

That is not a failure of the drug or of the person. It is what you would expect. The medication is supplying a signal that the body was not supplying on its own. Remove the signal and the old set point reasserts itself, often forcefully, because the body defends against weight loss with real physiological machinery.

The practical implication is that these are being used the way blood pressure medication is used: as long-term management of a chronic condition, not a course of treatment with an end date. That reframing matters for planning, for cost, and for how you think about yourself if you go back on after a gap.

Who these are for, and who they are not for

Approved uses generally include type 2 diabetes, chronic weight management for adults meeting body mass index criteria with or without weight-related conditions, and for some products, cardiovascular risk reduction or sleep apnea. Pediatric approvals exist for some products in specific age groups.

They are not for everyone. The class carries a boxed warning about thyroid C-cell tumors observed in rodents, and is contraindicated for people with a personal or family history of medullary thyroid carcinoma or the genetic syndrome MEN 2. They are not recommended in pregnancy. People with a history of pancreatitis, certain gastrointestinal conditions including gastroparesis, or active gallbladder disease need a careful conversation. People taking insulin or sulfonylureas may need those adjusted to avoid low blood sugar.

Only a clinician who knows your history can weigh this. What you can do is arrive knowing what to ask, and knowing that the brand name on the prescription may determine whether you can afford it.

Common questions

Is Ozempic the same as Wegovy?

Both contain semaglutide, the same active molecule. They are approved for different uses, come in different dose ranges, and are priced and covered differently by insurers. A prescriber chooses between them based on the condition being treated and what your plan will cover.

Is Mounjaro a GLP-1?

Mounjaro contains tirzepatide, which activates the GLP-1 receptor and also the GIP receptor. People commonly group it with GLP-1 medications, and it is often described more precisely as a dual GIP and GLP-1 receptor agonist.

Do GLP-1 medications work without changing how I eat?

They change how you eat, which is much of how they work. Most people on them find they want less food and feel full sooner. Trials paired the medication with nutrition and activity counseling, and protein intake and resistance training matter because some of the weight lost is muscle.

How long do you have to stay on a GLP-1?

There is no defined endpoint. Studies consistently show that stopping is followed by regain for most people, so these are generally used as ongoing treatment for a chronic condition. Whether to continue indefinitely is a decision to make with a prescriber, factoring in benefit, side effects, and cost.

Is there a pill version?

An oral semaglutide tablet exists and is approved for type 2 diabetes. It requires taking it on an empty stomach with a small amount of water and waiting before eating or drinking, because absorption through the stomach lining is limited and easily disrupted.

Sources

This is information, not medical advice. Strength from the Well is an independent publisher. Nothing here is a diagnosis, a prescription, or a recommendation to start or stop any treatment. Talk to a clinician who knows your history before you act on anything you read here — including anything you read here that contradicts them.